8-K: Gilead Sciences Reports Strong Q3 2024 Results, Raises Full-Year Guidance

Gilead Sciences announced robust third-quarter 2024 financial results, driven by strong product sales, leading to an increase in full-year revenue, operating income, and earnings per share guidance.

Summary

• Gilead Sciences reported a 7% increase in total revenue to $7.5 billion for the third quarter of 2024 compared to the same period in 2023.
• Product sales, excluding Veklury, also increased by 7% year-over-year to $6.8 billion.
• Biktarvy sales saw a significant 13% year-over-year increase, reaching $3.5 billion.
• Oncology sales grew by 6% year-over-year to $816 million.
• Diluted earnings per share (EPS) was $1.00, down from $1.73 in the same quarter of 2023, primarily due to a $1.75 billion pre-tax impairment related to acquired assets.
• Non-GAAP diluted EPS was $2.02, compared to $2.29 in the prior year, impacted by higher acquired IPR&D and tax expenses.
• The company's cash, cash equivalents, and marketable debt securities totaled $5.0 billion as of September 30, 2024, down from $8.4 billion at the end of 2023, mainly due to the $3.9 billion acquisition of CymaBay Therapeutics.
• Gilead generated $4.3 billion in operating cash flow during the third quarter and paid $983 million in dividends and repurchased $300 million of common stock.
• The company has increased its full-year 2024 guidance for product sales to $27.8 billion $28.1 billion, diluted EPS to $0.05 $0.25, and non-GAAP diluted EPS to $4.25 $4.45.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and increased guidance, but the significant IPR&D impairment and decrease in cash reserves temper the overall sentiment. The potential for lenacapavir is a strong positive.

Positives

• Gilead's third quarter results were the strongest of the year to date.
• The company experienced strong topline growth and disciplined operating expense management.
• Biktarvy sales showed significant growth, indicating strong market demand.
• The company is increasing its full-year revenue, operating income, and earnings per share guidance.
• Lenacapavir demonstrated a 96% reduction in HIV infections in a Phase 3 study.
• Gilead received FDA accelerated approval for Livdelzi for the treatment of primary biliary cholangitis.
• The company has a strategic collaboration with Genesis Therapeutics to discover and develop novel small molecule therapies.

Negatives

• Diluted EPS decreased to $1.00 from $1.73 in the same period last year, primarily due to a $1.75 billion pre-tax IPR&D impairment.
• Non-GAAP diluted EPS also decreased to $2.02 from $2.29 in the same period last year.
• Cash, cash equivalents, and marketable debt securities decreased from $8.4 billion to $5.0 billion, mainly due to the acquisition of CymaBay Therapeutics.
• Yescarta sales decreased by 1% due to increased competition.
• The company plans to voluntarily withdraw the U.S. accelerated approval of Trodelvy for use in pre-treated adult patients with locally advanced or metastatic urothelial cancer.

Risks

• The company's ability to achieve its anticipated full-year 2024 financial results is subject to the uncertainty of the amount and timing of Veklury revenues.
• There are risks associated with the company's ability to make progress on its long-term ambitions or priorities.
• The company faces risks related to patent protection and potential loss of exclusivity for its products.
• Clinical trials may not progress as anticipated, and results may not warrant further development of product candidates.
• Regulatory approvals may not be received in a timely manner or at all, and approvals may be subject to limitations.
• The company faces pricing and reimbursement pressures from government agencies and other third parties.
• Market share and price erosion may occur due to the introduction of generic versions of Gilead products.
• Physicians and patients may not see advantages of Gilead's products over other therapies.

Future Outlook

Gilead has increased its full-year 2024 guidance for product sales to $27.8 billion $28.1 billion, diluted EPS to $0.05 $0.25, and non-GAAP diluted EPS to $4.25 $4.45. The company expects to file for FDA approval of lenacapavir before the end of the year.

Management Comments

• Daniel O'Day, Gilead's Chairman and Chief Executive Officer, stated that the third quarter results were the strongest of the year to date.
• He also mentioned that the company is increasing its full-year revenue, operating income, and earnings per share guidance due to strong topline growth and disciplined operating expense management.
• O'Day expressed excitement about increasing the company's impact for patients and communities in the months ahead, including the launch of Livdelzi and the potential launch of lenacapavir.

Industry Context

Gilead's strong performance in HIV and oncology aligns with the broader trend of growth in these therapeutic areas within the pharmaceutical industry. The development and potential approval of lenacapavir for HIV prevention could be a significant advancement in the field. The company's strategic collaborations and acquisitions also reflect the industry's focus on innovation and expanding product pipelines.

Comparison to Industry Standards

• Gilead's 7% revenue growth is solid, but it is important to compare this to peers like AbbVie, which has seen strong growth in its immunology and oncology portfolios, and Bristol Myers Squibb, which has a diverse portfolio including oncology and cardiovascular drugs.
• The 13% growth in Biktarvy sales is impressive and positions it well against competitors in the HIV market such as GSK's Dovato and ViiV Healthcare's portfolio.
• The 6% growth in oncology sales is moderate compared to companies like Merck and Roche, which have seen higher growth rates in their oncology divisions due to blockbuster drugs.
• The $1.75 billion IPR&D impairment is a significant charge and should be compared to similar charges taken by other companies in the sector to understand if this is an industry-wide trend or specific to Gilead.
• Gilead's cash position of $5.0 billion is lower than some of its peers, which may impact its ability to make further acquisitions or investments in R&D. Companies like Johnson & Johnson and Pfizer typically maintain higher cash reserves.

Stakeholder Impact

• Shareholders will benefit from the increased full-year guidance and the declared quarterly dividend.
• Employees may see increased job security and potential for growth due to the company's positive performance.
• Patients will benefit from the development and commercialization of new treatments, such as lenacapavir and Livdelzi.
• Customers will have access to a broader range of innovative medicines.
• Suppliers and creditors will benefit from the company's financial stability and growth.

Next Steps

• Gilead plans to file for FDA approval of lenacapavir for HIV prevention before the end of the year.
• The company will continue to advance its oncology pipeline, including the partnered CAR T anito-cel.
• Gilead will continue to commercialize Livdelzi for primary biliary cholangitis.
• The company will continue to execute its strategic collaboration with Genesis Therapeutics.

Key Dates

Keywords

Gilead Sciences, Financial Results, Q3 2024, Biktarvy, Oncology, HIV, Lenacapavir, Veklury, Earnings Per Share, Product Sales, Livdelzi, Trodelvy, Yescarta, Cell Therapy